Spero Therapeutics
400 Technology Square, 10th Floor
Cambridge
Massachusetts
02139
United States
Website: http://sperotherapeutics.com
About Spero Therapeutics
51 articles with Spero Therapeutics
-
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
-
Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
6/20/2019
Spero Therapeutics, Inc. announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis, an indication that is designated as a critical concern by the World Health Organization.
-
Spero Therapeutics and the Gates Medical Research Institute Collaborate on Tuberculosis Treatment
6/20/2019
There are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. If successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic. -
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
3/14/2019
Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19
-
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of DirectorsSpero adds broad leadership and scientific expertise to its Board of Directors with appointment of John Pottage
8/14/2018
Spero Therapeutics, Inc. announced the appointment of John C. Pottage, Jr., M.D. to its Board of Directors, effective immediately prior to the next regularly scheduled meeting of the Board of Directors on September 21, 2018.
-
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
8/9/2018
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-end
-
Shares of Cambridge, Mass.-based Spero Therapeutics are climbing this morning after the company announced it secured up to $54 million from the government to support its development of SPR944 as a potential treatment against drug-resistant infections.
-
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
7/16/2018
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994
-
Spero Therapeutics Announces Pricing of Securities Offering
7/13/2018
Spero Therapeutics, Inc. announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock.
-
Spero Therapeutics Announces Proposed Offering of Common Stock
7/9/2018
Spero Therapeutics, Inc. announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.
-
Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994
7/9/2018
Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses
-
Spero Announces Appointment of David P. Southwell to its Board of Directors
2/1/2018
Broad leadership and financial expertise adds to our board’s breadth of talent and background.
-
Motif Bio PLC, Spero Therapeutics and Vical Incorporated Join Antimicrobials Working Group
1/30/2018
The Antimicrobials Working Group announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations.
-
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
1/4/2018
Dr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials.
-
Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update
12/15/2017
The Company reported a net loss of $(12.1) million, or basic and diluted net loss per common share of $(36.02), for the third quarter of 2017.
-
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
-
Spero Therapeutics Announces Underwriters’ Option Exercise
11/13/2017
Spero’s common stock began trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO”.
-
Spero Therapeutics Announces Closing of Initial Public Offering
11/7/2017
The company has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its common stock at the initial public offering price.
-
Spero Therapeutics Announces Pricing of Initial Public Offering
11/2/2017
Spero Therapeutics, Inc.’s shares are expected to begin trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO.”
-
Spero Therapeutics Launches Initial Public Offering
10/23/2017
Spero has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock.